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Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical
management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars
planavitrectomy).Adjunctivepharmacologictherapies(intravitrealtriamcinoloneacetonideandanti-vascularendothelialgrowth
factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy.
Other medications under investigation include the ﬂuocinolone acetonide implantable device, extended-release dexamethasone
implant, oral ruboxistaurin, and intravitreal hyaluronidase.
Copyright © 2007 S. G. Schwartz and H. W. Flynn Jr. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Despite advancements in the delivery of ophthalmologi-
cal care, diabetic retinopathy remains a major cause of
preventable blindness [1]. The two most important visual
complications of diabetic retinopathy are diabetic macular
edema (DME) and proliferative diabetic retinopathy (PDR).
Glycemic control [2, 3] and photocoagulation [4, 5]h a v e
been standard treatments for both DME and PDR for over
3 decades. Nevertheless, some patients suﬀer permanent vi-
sual loss despite prompt and appropriate therapy.
In recent years, further advances in pharmacotherapy
have shown promise in the treatment of diabetic retinopa-
thy. The three major classes of medications currently being
studied are corticosteroids, vascular endothelial growth fac-
tor (VEGF) antagonists, and miscellaneous agents. Multiple
clinical series have been reported (Table 1), and many more
are ongoing or being planned (Table 2).
2. CORTICOSTEROIDS
Corticosteroids may work through multiple mechanisms of
action. In addition to their well-known anti-inﬂammatory
eﬀects, corticosteroids may cause downregulation of VEGF
[6, 7]. Intravitreal triamcinolone acetonide (IVTA) is com-
monly used today as an oﬀ- l a b e la d j u n c t i v et r e a t m e n to f
DME (Figure 1). Other intravitreal corticosteroids under
study include a sustained-release device containing ﬂuo-
cinolone acetonide (Retisert; Bausch & Lomb, Rochester,
NY)andextended-releasedexamethasoneinabiodegradable
polymer (Posurdex, Allergan, Irvine, Calif).
2.1. Triamcinoloneacetonide
Although intravitreal triamcinolone acetonide (Kenalog 40,
Bristol-Myers Squibb, Princeton, NJ) has been administered
for many years [8], its use has become more common
since 2002 [9–11]. Recent prospective, randomized clini-
cal trials have demonstrated generally favorable outcomes
[12, 13]. The Diabetic Retinopathy Clinical Research net-
work (DRCR.net) has completed enrollment on a three-year,
randomized, prospective, multicenter clinical trial compar-
ing two doses (1mg and 4mg) of preservative-free IVTA (Al-
lergan, Irvine, Calif) with modiﬁed early treatment diabetic
retinopathystudy(ETDRS)photocoagulationforDME.Fur-
thermore,IVTAmaybeausefuladjuncttophotocoagulation
for PDR, perhaps by decreasing the macular edema some-
times worsened by the treatment [14, 15].
The most important complication of IVTA is increased
intraocularpressure(IOP)resultinginsecondaryopen-angle
glaucoma, which sometimes may be severe [16] and in-
tractable [17, 18]. Elevation of IOP up to 24mm Hg may oc-
cur in about 40% of patients, usually within about 3months
[19]. The second most important complication of IVTA is
cataract formation, which may become visually signiﬁcant in
about half of eyes within 1year [20].2 Experimental Diabetes Research
The rates of injection-related endophthalmitis following
IVTA have been reported to be in the range of 0.099%–
0.87% per injection [21, 22]. The incidence of pseudoen-
dophthalmitis, due to migration of triamcinolone acetonide
crystals into the anterior chamber, is probably higher than
that of infectious endophthalmitis. Other reported compli-
cations of IVTA (and of any intravitreal injection) include
retinal detachment, lens trauma, and vitreous hemorrhage.
The use of peribulbar, rather than intravitreal, triamci-
noloneacetonideoﬀersreducedrisksofendophthalmitisand
perhaps other complications. Peribulbar triamcinolone ace-
tonidemayhavesomelimitedeﬃcacyforpatientswithDME
[23,24]althoughthebulkofthecurrentliteratureappearsto
indicate that IVTA is more eﬀective [25, 26]. DRCR.net has
recentlypublished a phase2 randomized, prospective, multi-
center clinical trial comparing peribulbar triamcinolone ace-
tonide with and without photocoagulation. Peribulbar tri-
amcinolone did not signiﬁcantly improve vision in patients
with mild DME [48]. Neither peribulbar triamcinolone nor
IVTA appears to oﬀer long-term eﬃcacy for DME, which has
led to the investigation of various extended-release corticos-
teroids.
2.2. Fluocinoloneacetonide
The ﬂuocinolone acetonide intravitreal implant (Retisert) is
FDA-approved for the treatment of chronic, noninfectious
posterior segment uveitis [27]. Although the device was also
studied in patients with DME, no speciﬁc results has been
published in the peer-reviewed literature at this time [28].
2.3. Extended-releasedexamethasone
A bioerodable, extended-release dexamethasone implant
(Posurdex, Allergan, Irvine, Calif) has shown favorable out-
comes in the treatment of macular edema due to various eti-
ologies, including DME, in a recent phase 2 study [29]. A
p h a s e3t r i a li su n d e r w a y .
3. VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) INHIBITORS
Vascular endothelial growth factor (VEGF) increases retinal
vascular permeability, causes breakdown of the blood-retinal
barrier, and results in retinal edema [30]. VEGF is upregu-
lated in diabetic retinopathy [31] and is present in increased
levels in the aqueous and vitreous humor of patients with
PDR [32, 33]. At least 5 isoforms of VEGF are known [34].
Three currently available anti-VEGF agents are pegaptanib,
bevacizumab, and ranibizumab.
3.1. Pegaptanib
Pegaptanib (Macugen, OSI/Eyetech, Melville, NY) is a pe-
gylated aptamer directed against the VEGF-A 165 isoform.
It was the ﬁrst FDA-approved ophthalmologic anti-VEGF
agent,forthetreatmentofchoroidalneovascularizationfrom
age-related macular degeneration (AMD) [35]. In a phase 2,
prospective clinical trial, pegaptanib appeared to improve
anatomic and visual outcomes in patients with DME [36].
Retrospective analysis of these data demonstrated some eﬃ-
cacy on retinal neovascularization as well [37]. Phase 3 trials
of pegaptanib for DME are currently being conducted.
3.2. Bevacizumab
Bevacizumab (Avastin, Genentech, Inc., South San Fran-
cisco, Calif), a full-length recombinant humanized antibody,
is active against all isoforms of VEGF-A. It is FDA-approved
as an adjunctive systemic treatment for metastatic colorec-
tal cancer [49]. Although oﬀ-label systemic bevacizumab has
demonstrated some eﬃcacy for exudative AMD [50], the
agent has shown greater promise as an intravitreal medica-
tion. Case reports and small observational series have been
reported using oﬀ-label intravitreal bevacizumab to treat ex-
udativeAMD[51],macularedemafromnonischemiccentral
retinal vein occlusion [52], iris neovascularization [53, 54],
pseudophakic cystoid macular edema [55], and other dis-
eases. Small, nonrandomized pilot studies have documented
some eﬃcacy against diﬀuse DME [56] and various compli-
cations of PDR [38–40]( Figure 2).
DRCR.net has completed enrollment on a phase 2, pro-
spective, randomized, multicenter clinical trial to determine
thesafetyandpossiblebeneﬁtsofthisagent.Plansforaphase
3 trial of two doses of an intravitreal anti-VEGF agent versus
modiﬁed ETDRS grid laser photocoagulation for DME are
under discussion.
3.3. Ranibizumab
Ranibizumab (Lucentis, Genentech, Inc., South San Fran-
cisco, Calif), a recombinant humanized antibody fragment,
is active against all isoforms of VEGF-A. Intravitreal rani-
bizumab is FDA-approved for the treatment of exudative
AMD [57, 58]. Two pilot studies of ranibizumab demon-
strated some eﬃcacy in the treatment of DME [41, 42].
DRCR.net is planning two phase 3, prospective, randomized,
multicenter trials comparing patients. In the ﬁrst trial, pa-
tients with DME and no PDR will be randomized to: (1)
modiﬁed ETDRS grid laser photocoagulation; (2) photo-
coagulation before ranibizumab; (3) photocoagulation plus
IVTA; or (4) ranibizumab before photocoagulation. In the
second trial, patients with DME and PDR will be random-
ized to: (1) modiﬁed ETDRS grid laser photocoagulation
plus scatter photocoagulation; (2) modiﬁed ETDRS grid
laser photocoagulation plus scatter photocoagulation plus
ranibizumab; or (3) modiﬁed ETDRS grid photocoagulation
plus scatter photocoagulation plus IVTA.
The risk of injection-related endophthalmitis with the
anti-VEGFagentsisvariable,butappearstobelowerinmore
recent studies. Major prospective clinical trials of pegaptanib
and ranibizumab reported rates between 0.7%–1.6% per eye
[35, 57–59]. Most eyes in these reports received a series of
injections, and a recent observational case series reported an
incidence of 0.014% per injection for bevacizumab [60].S. G. Schwartz and H. W. Flynn Jr. 3
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Figure 1: Intravitreal triamcinolone acetonide for diabetic macular edema. A patient presented with diabetic macular edema, visual acuity
20/60. Fundus photography (a) and optical coherence tomography (OCT) (b, c) are shown. The patient was treated with intravitreal triam-
cinolone acetonide. One month after treatment, visual acuity improved to 20/40, with improvement of macular edema on photography (d)
and OCT (e, f). Four months after treatment, visual acuity improved to 20/20, with further improvement of macular edema on photography
(g) and OCT (h, i).
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Figure 2: Intravitreal bevacizumab for proliferative diabetic retinopathy. A patient presented with proliferative diabetic retinopathy. Fundus
photography (a) and ﬂuorescein angiography (b) are shown. The patient was treated with intravitreal bevacizumab. Followup ﬂuorescein
angiography demonstrated improvement in angiographic leakage (c). Panretinal photocoagulation was then applied (d). (Case courtesy of
Geeta Lalwani, MD, and Carmen A. Puliaﬁto, MD, MBA.)4 Experimental Diabetes Research
Table 1: Selected published clinical series evaluating pharmacotherapies for advanced diabetic retinopathy. CMT: central macular thickness
(assessed by optical coherence tomography), FA: ﬂuorescein angiography, IVTA: intravitreal triamcinolone acetonide, DME: diabetic macu-
lar edema, NV: neovascularization, PDR: proliferative diabetic retinopathy, TA: triamcinolone acetonide, VA: visual acuity, and VH: vitreous
hemorrhage.
Study (reference) Reported patients Reported eyes Medication Indication and outcome
measures
Eﬃcacy
Martidis et al. [9]1 6 1 6 IVTA DME, VA, CMT Favorable
Gillies et al. [12]4 36 9 IVTA DME, VA Favorable
Lam et al. [13]6 3 6 3 IVTA DME, VA, CMT Favorable
Tunc et al. [23]5 0 6 0 Peribulbar TA DME, VA, FA Favorable
Bakri et al. [24]5 0 6 3 Peribulbar TA DME, VA Favorable
Cardillo et al. [25]1 2 2 4 Peribulbar TA DME, VA, CMT Unfavorable
Bonini-Filho et al. [26]3 6 3 6 Peribulbar TA DME, VA, CMT Unfavorable
Kuppermann et al. [29] 286 286 Extended-release
dexamethasone DME, VA, CMT Favorable
Cunningham et al. [36] 172 172 Pegaptanib DME, VA, CMT,
photocoagulation
Favorable
Adamis et al. [37]1 6 2 0 Pegaptanib PDR, retinal NV Favorable
Spaide et al. [38]2 2 Bevacizumab PDR, retinal NV, VH Favorable
Jorge et al. [39]1 5 1 5 Bevacizumab PDR, VA, retinal NV, FA Favorable
Avery et al. [40]3 2 4 5 Bevacizumab PDR, VA, iris and retinal
NV, FA
Favorable
Chun et al. [41]1 0 1 0 Ranibizumab DME, VA, CMT Favorable
Nguyen et al. [42]1 0 1 0 Ranibizumab DME, VA, CMT Favorable
PKC-DRS [43] 252 504 Ruboxistaurin DME, PDR, VA,
Photocoagulation
Favorable
PKC-DRS2 [44] 685 1370 Ruboxistaurin DME, VA,
Photocoagulation
Favorable
PKC-DMES [45] 686 1372 Ruboxistaurin DME, Photocoagulation Unfavorable
Strom et al. [46]4 15 5 Ruboxistaurin DME, VA, vitreous
ﬂuorometry
Somewhat favorable
Kuppermann et al. [47] 1125 1125 Hyaluronidase VH, anatomic clearance,
VA
Favorable
DRCR.net et al. [48] 109 129 Peribulbar TA DME, VA, CMT Unfavorable
Table 2: Selected ongoing clinical trials evaluating pharmacotherapies for advanced diabetic retinopathy. DME: diabetic macular edema,
DRCR.net: Diabetic Retinopathy Clinical Research network, PF/IVTA: preservative-free intravitreal triamcinolone acetonide, PDR: prolifer-
ative diabetic retinopathy, and TA: triamcinolone acetonide.
Sponsor Medication Indication Status
DRCR.net (phase 3) PF/IVTA DME Completed enrollment
Bausch & Lomb Fluocinolone implant DME Completed enrollment
Allergan (phase 3) Extended-release dexamethasone DME In planning stages
OSI/Eyetech Pegaptanib DME Enrolling patients
DRCR.net (phase 2) Bevacizumab DME Completed enrollment
Genentech Ranibizumab DME Enrolling patients
DRCR.net (phase 3) Ranibizumab or IVTA DME with no PDR Enrolling patients
DRCR.net (phase 3) Ranibizumab or IVTA DME with PDR Enrolling patients
4. OTHER AGENTS
4.1. Ruboxistaurin
TheenzymeproteinkinaseCβ (PKCβ)isacti vat edb yVEGF
and appears to increase various systemic complications, in-
cluding diabetic retinopathy [61]. Ruboxistaurin (Arxxant,
EliLillyandCompany,Indianapolis,Ind),anorallyadminis-
teredPKCβinhibitor,hasshowneﬃcacyagainstDMEintwo
separate phase 3 trials [43, 44], although a recent study re-
ported that treatment did not delay disease progression overS. G. Schwartz and H. W. Flynn Jr. 5
Table 3: Guidelines for pharmacologic treatment of advanced diabetic retinopathy.
(A) Clinically signiﬁcant macular edema (CSME)
(1) Evaluation
(a) Initial diagnosis
(i) Complete eye examination
(ii) Fundus photography, ﬂuorescein angiography, optical coherence tomography (OCT)
(b) Followup
(i) Clinical examination
(ii) OCT
(2) Treatment
(a) First-line therapy
(i) Focal or modiﬁed ETDRS grid photocoagulation for focal or diﬀuse CSME
(ii) Intravitreal pharmacotherapies ± photocoagulation for more advanced, diﬀuse CSME
(b) For persistent or recurrent CSME (visual acuity <20/40)
(i) Repeat photocoagulation
(ii) Intravitreal triamcinolone acetonide or intravitreal antivascular endothelial growth factor (VEGF) agent
(c) For CSME refractory to photocoagulation and intravitreal pharmacotherapies, consider pars plana vitrectomy (PPV)
(i) No traction: PPV with internal limiting membrane (ILM) peeling
(ii) Taut posterior hyaloid face or vitreomacular traction syndrome: PPV and ILM peeling
(B) Proliferative diabetic retinopathy (PDR)
(1) Evaluation
(a) Initial diagnosis
(i) Complete eye examination
(ii) Fundus photography, ﬂuorescein angiography (sometimes), optical coherence tomography (OCT), echography (if
necessary)
(b) Followup
(i) Clinical examination
(ii) OCT for evaluation of macular disease
(2) Treatment
(a) First-line therapy
(i) In eyes with clear media: panretinal photocoagulation (PRP)
(ii) In eyes with vitreous hemorrhage and no retinal detachment: consider intravitreal anti-VEGF agent, with PRP after
clearing
(iii) Ineyeswithtractionretinaldetachment,considerintravitrealanti-VEGFagentbeforeparsplanavitrectomytoreduce
vascularity
(iv) In eyes with attached posterior hyaloid, consider use of intravitreal triamcinolone acetonide to assist in hyaloid re-
moval
(b) For combined PDR/CSME
(i) Consider medical options
(1) Intravitreal anti-VEGF agent or hyaluronidase for vitreous hemorrhage
(2) Standard focal or modiﬁed grid and PRP
(ii) Consider standard surgical options for more advanced disease
(1) Nonclearing vitreous hemorrhage
(2) Advanced traction retinal detachment6 Experimental Diabetes Research
a30-monthfollowup[45].Asmallerstudynotedthatrubox-
istaurin treatment was associated with a reduction in retinal
vascular leakage, as measured by vitreous ﬂuorometry, but
visual acuity was not aﬀected [46]. Although Lilly received
an approvable letter from the FDA on August 18, 2006, the
FDA requested an additional, 3-year, Phase 3 clinical trial to
collect additional eﬃcacy data in spite of an appeal with ad-
ditional data.
4.2. Hyaluronidase
In an attempt at pharmacologic vitreolysis, intravitreal pu-
riﬁed ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals,
Irvine,Calif)wasproposedtoaccelerateclearanceofvitreous
hemorrhage from PDR and other causes. A recent phase 3
prospective clinical trial showed some favorable eﬃcacy [47]
and safety [62]o u t c o m e sf o rt h ec l e a r a n c eo fv i t r e o u sh e m -
orrhageduetoallcauses,butthisagentisnotcurrentlyFDA-
approved for this indication.
5. CLINICAL GUIDELINES
Although none of the pharmacologic agents discussed above
is FDA-approved for treatment of patients with diabetic
retinopathy, oﬀ-label treatment can be considered for pa-
tientsunresponsivetotraditionalstandardcare.Theseguide-
lines are summarized in Table 3.
In patients with diabetic macular edema not responsive
to photocoagulation, either IVTA or an intravitreal anti-
VEGF agent may be considered as second-line treatments.
At this time, there are no published head-to-head compar-
isons of IVTA versus the anti-VEGF agents for this disease,
although the pending DRCR.net trials may provide useful
guidelines in this regard. Triamcinolone may be relatively
more eﬃcacious for DME, while the anti-VEGF agents ap-
pear more eﬃcacious for PDR. Triamcinolone is consider-
ably less expensive than the anti-VEGF agents, but is associ-
ated with risks of elevated IOP, cataract, and pseudoendoph-
thalmitis.
In patients with complications of PDR not amenable to
photocoagulation, intravitreal anti-VEGF agents may pro-
duceshort-termstabilizationorregressionofirisand/orreti-
nal neovascularization. In most patients, however, photoco-
agulation will eventually be necessary.
Intravitreal anti-VEGF agents may be helpful in patients
with dense vitreous hemorrhage and patients with glaucoma
secondarytoneovascularization.IfB-scanechographyshows
no evidence of retinal detachment, these agents may pro-
vide useful short-term anatomic improvement, until deﬁni-
tive photocoagulation can be given, or to reduce intraopera-
tive bleeding in eyes with neovascular glaucoma.
6. SUMMARY
Clinical experience with pharmacologic treatment for dia-
betic retinopathy continues to increase and reported out-
comes in observational case series are promising. At this
time, improved metabolic control and local ocular treat-
ments(photocoagulationandvitrectomy)remaintheproven
treatments, through evidence-based medicine. As prospec-
tive randomized clinical trials accumulate data, the role of
pharmacologic treatments will become clearer.
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